The Effect of Weight Loss on Psoriasis Area Severity Index in Adult Psoriasis Patients
Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER, HOUSTON · Jun 3, 2010
Trial Information
Current as of July 03, 2025
Withdrawn
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • \>18 years of age
- • A Body Mass Index (BMI) \>/= 30
- • Subject has plaque psoriasis
- • A Psoriasis Area Severity Index (PASI) score \>/= 10 or a total body surface area (BSA) affected by psoriasis \>/= 10%
- • Capable of reading, understanding, and signing a consent form
- • Females of childbearing potential must have negative urine pregnancy test on Day 0, and agree to a medically effective method of birth control (as determined by the investigator)
- Exclusion Criteria:
- • Already participating in a study for weight loss or a study of other psoriasis treatments
- • If they are on systemic therapy for their psoriasis
- • Female subjects who are pregnant or planning to become pregnant
- • Patients with a history of anorexia nervosa, bulimia, or other diseases that would make a weight loss program a risk to their health
- • Subjects unable to comply with study protocol
About The University Of Texas Health Science Center, Houston
The University of Texas Health Science Center at Houston (UTHealth) is a leading academic institution dedicated to advancing health through education, research, and clinical practice. As a prominent sponsor of clinical trials, UTHealth leverages its extensive resources and expertise in biomedical research to facilitate innovative studies aimed at improving patient outcomes. The institution is committed to fostering a collaborative environment that promotes scientific discovery and the translation of research findings into effective healthcare solutions, all while adhering to the highest ethical standards and regulatory guidelines. With a multidisciplinary approach, UTHealth plays a critical role in addressing complex health challenges and enhancing the quality of life in diverse communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Adelaide Hebert, MD
Principal Investigator
University of Texas Medical School - Houston
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials